Incubate Coalition
Making Medicine
There's a scientific breakthrough in your medicine cabinet. But how did it get there? At a time when medicines are helping us all live longer and healthier lives, this podcast will explore where these taken-for-granted miracles come from, how many of them almost never happened, where the life science ecosystem is taking us next, and most importantly, what it means for patients. From chance meetings that led to new ideas, to risky investments that never pay off, hear from the people behind today's and tomorrow's treatments, vaccines, technologies, devices, and yes, cures. In this golden age of...
Be sure to visit the podcast's website and support the creator: www.spreaker.com
Author
Incubate Coalition
Category
Podcast website
Latest episode
Nov 19, 2026
Where to listen?
Podcasts in the app Replaio Radio Coming soonPodcasts are coming to the app soon. Install now and be the first to see a whole new take on podcasts
Episodes
Protecting Innovation: Small Molecules and the Future of Medicine 13.09.2024 17:38
Science should lead our policy decisions—not the other way around. In this episode, Kirsten Axelson , Senior Policy Lab Advisor at Incubate Coalition , dives deep into the power of small molecule medicines, the promise they hold for the future, and how our current policy landscape may upend their development. This conversation focuses on Incubate Policy Lab’s most recent white paper, which shed...
CEO Series Part 1: Sherine Chan, CEO & Co-founder of Neuroene Therapeutics 28.06.2024 17:04
As part of our inaugural CEO series, we're excited to welcome Sherine Chan , the CEO and Co-Founder of Neuroene Therapeutics . In this episode, Sherine shares her journey from academia to helming a cutting-edge biotech company. She explores the groundbreaking work her company is pioneering in targeting the powerhouses of cells: mitochondria. Sherine also dives into the influence of the Inflation R...
Dispelling Misconceptions in Biopharmaceutical IP Regulation 03.05.2024 25:21
On World IP Day, Kirsten Axelsen , Senior Advisor of the Incubate Policy Lab , joins host John Stanford to announce the newest whitepaper, delve into the myths and realities surrounding IP in the pharmaceutical industry, explore the dynamics of patent regulations, and touch on the contentious discussions around patent thickets and pharmaceutical pricing under new legislative environments like the...
When the Feds Come Marching In: A Deep Dive on The Bayh-Dole Act 11.04.2024 22:08
Joe Allen , Executive Director of The Bayh-Dole Coalition , was at the forefront of the Bayh-Dole Act back in December 1980, which allowed researchers to own inventions resulting from federally funded research. However, 43 years later, the March-In Rights framework proposed by the Biden administration threatens to weaken America’s innovation. In this episode, Joe delves into the potential implicat...
Beyond Medicine: Solving Disparities in Cancer Care 13.09.2023 25:07
How can we create better outcomes for cancer patients? That’s the big goal Mohit Manrao is aiming for in his work as SVP & Head of US Oncology at AstraZeneca . In this episode, Mohit shares his perspective on the future of oncology and the pursuit of patient-centric care in a post-Inflation Reduction Act world. Join us as we discuss: AstraZeneca's goal of launching 15 new drugs by 2030 Solving...
Balancing Access and Affordability in the Future of Healthcare 23.08.2023 25:49
Can we create a future healthcare system that is accessible and affordable for all patients? That’s the major question that Mary R. Grealy , CEO of Healthcare Leadership Council, is trying to answer through her work. Mary, a former speech pathologist turned lawyer, shares insights from her unique journey from the healthcare field to advocating for patient-centered, value-based healthcare systems....
Making Patients the Center of U.S. Healthcare Reform 11.05.2023 34:45
With recent movement in healthcare including President Biden’s Cancer Moonshot and the Inflation Reduction Act, one thing is clear: American healthcare is at a crossroads. As we begin to tackle the conversation of healthcare reform, how can we rebuild the system around patients? In this episode, MacKay Jimeson , Executive Director of The Patient Access & Affordability Project at Patients Risin...
Innovations in Women’s Health & Entrepreneurship 31.03.2023 21:53
Even though 80% of the household decisions around health are made by women, only 4% of research and funding goes towards women’s health research. In today’s episode, Natalie Buford-Young , Chief Executive Officer at Springboard Enterprises , joins us to discuss Springboard’s mission and how they are exploring a designated network to create pathways for emerging female innovators. We also get to he...
The Inflation Reduction Act: A Big Issue for Small-Molecule Medicine 24.03.2023 30:49
Runaway inflation and economic instability is terrible for just about everybody, but are efforts to tackle this problem creating more? To answer that, Kirsten Axelsen, Senior Policy Advisor at DLA Piper, joins the show to break down all the effects The Inflation Reduction act is having upon medicine, We discuss: The potential negative impacts on small-molecule medicine How the act affects patents...
From the JP Morgan Conference: The Impact of the Inflation Reduction Act 23.01.2023 28:20
John was at the JP Morgan conference and is here to discuss the key takeaways of the Inflation Reduction Act: the small-molecule penalty, the value of small-molecule drugs, the importance of incentivizing post-approval research, intellectual property, and non-coverage decisions at CMS. You’ll also hear John’s take on the demand for a more pro-patient agenda. There was a lot of focus on the role of...
Drug Investment Under the Inflation Reduction Act 12.12.2022 57:17
How will the Inflation Reduction Act affect life sciences startups, current and future revenues, and drug investment? What will happen to patients amidst the aftermath of unintended consequences? There aren’t too many people who know more about the ins and outs than the fine folks at DLA Piper. One of the biggest interventions in drug pricing since the Medicare Modernization Act was passed, listen...
The Three Pillars of Bio & Med Tech Investing and Industry Impact of DEI 28.09.2022 41:00
When you’re working to make good investments in bio and med tech there are three key pillars to consider: science, the management team and finance. But how does it all come together in the end? Find out in the latest episode with Christine Brennan, Managing Director, Vertex Venture HC as we talk about Vertex’s investment philosophy, why DEI inclusion is vital for industry, and what investments c...
Understanding Health Equity w/ Dr. Jerome Adams 19.07.2022 36:35
Everyone wants to make healthy choices. But we don't always have an opportunity to make healthy choices. In today’s episode, we speak with Dr. Jerome Adams, Executive Director of Health Equity Initiatives at Purdue University and the 20th Surgeon General of the United States, about the need for proactive accessible health care, the economic burden of inaccessible healthcare, and why people need t...
Addressing The Overlooked AMR Problem w/ Dr. Henry Skinner 24.05.2022 42:24
Investors are logical people. They invest in medicines that they expect will give them a return. Right now, there’s far too little investment in developing new antibiotics. The pipeline of treatment is thin, but the need is greater than ever. Enter the AMR Action Fund. Hear our conversation with Dr. Henry Skinner, Chief Executive Officer at AMR Action Fund about: The increasing cost of AMR and pol...
Pro-Patient Reforms: The Outlook for 2022 19.04.2022 17:23
We’ll be the first to say that the healthcare system is broken, especially in patient access complexity. However, we see three areas where we can execute actionable change for patients in 2022: intellectual property, mergers and acquisitions, and the FDA’s reauthorization. In this episode, Coalition Manager and podcast host Ashlyn Roberts interviews John Stanford, Executive Director at Incubate Co...
How Better Data Fosters Health Equity w/ Kirsten Axelsen 05.04.2022 26:29
If we want data and clinical trials that meaningfully represent the population of people who take the drug, we’ll need to do more than just issue guides. In this episode, we interview returning guest Kirsten Axelsen,Senior Advisor for Charles River Associates, about making medicine more accessible to lower income people and creating a more equitable health system with better data. Join us as we di...
Winning the Drug Development Relay Race w/ Johannes Fruehauf 11.02.2022 33:39
Drug development is a relay race because you pass the baton to the next runner who will take it to the next level. You are proud to have made it onto the stairs at the end of the race not as an individual but as a huge team of experts of subsequent talents. In this episode we interview Johannes Fruehauf, Founder and CEO at LabCentral/BioLabs, about how the relay race metaphor shapes our understand...
New Modalities: The Future of Drug Development w/ Jean-Francois Formela 21.12.2021 35:03
Drug policy debate today is like a wetland. It’s the heart of the ecosystem that has to be preserved at all costs — or else we lose the wetlands, the shore, everything. In this episode, we interview Jean-Francois Formela, Partner at Atlas Venture, about what brought him to Washington and his views on the government’s role in drug development. Join us as we discuss: Where are we going in drug devel...
The Investor’s Paradox, Drug Development, & Price Controls w/ Peter Kolchinsky 02.11.2021 55:54
Today’s guest describes drug development in the American healthcare market with the analogy of mortgages and rents. People would rather pay higher mortgages because they are finite than pay rent indefinitely. Market-based pricing means that drugs will cost more until they become generic, whereas price control means paying rent forever. In this episode, we interview Peter Kolchinsky, Managing Partn...
MIT Takeover: A MedTech-VC Partnership Working to Reduce Parkinson’s Tremors 19.10.2021 26:43
How does an MIT senior year capstone project evolve into an early-stage biotech that creates wearable solutions for Parkinson’s tremors? Listen to Daniel Carballo speak about the story of Encora Therapeutics in our MIT takeover episode, hosted by guest Lindsay Androski Founder, President, and CEO at Roivant Social Ventures and President, Board Member at Incubate Coalition. In this episode, we dis...
Venture Capital Investors: The Underwriters of Innovation w/ Janis Naeve, Brian Bradbury, and Alan Brookhart 28.09.2021 34:16
As we follow innovation along the R&D value chain, we come across some compelling contributions to the healthcare ecosystem. Venture capital investors. Causal inference. Real world evidence. In this episode, we interview three guests about a collaboration story that represents the best of a healthy healthcare ecosystem: Janis Naeve, Managing Director, Amgen Ventures at Amgen and Incubate Board Tre...
The Hidden Cost of Price Control Policies w/ Kirsten Axelsen 14.09.2021 25:47
The price control policies that are being discussed in Congress have the potential to harm innovation in the life science industry. But how, exactly? In this episode, we interview Kirsten Axelsen, Senior Advisor at Charles Rivers Associates , about what would change in biopharma if price controls were implemented. In this episode, we discuss: The close relationship between economy and drug develop...
You Cannot Make Medicine Alone: Relationships & Mentoring w/ Imran Nasrullah 27.07.2021 27:13
What goes into a bottle of new medicine is more than the proverbial 15 years and $2 billion. It takes great science, certainly, but it also takes 15 years of relationships. No one can make medicine alone, not even Big Pharma. Collaboration, innovation, and industry relationships are key to bringing life-saving medicine to market. In this episode, I interview Imran Nasrullah, Vice President & Head,...
Improving the Standard of Care w/ Patients in Mind 13.07.2021 29:34
High cost out-of-pocket drugs and obstacles to reduce those prices for patients plague the health industry. With patients in mind, organizations are looking to invest and bring drugs directly to market. Gaurav Gupta and Hugo Beekman, Co-Founders of Ascendant BioCapital, join the show to discuss their organization and how they’re focusing on drugs that truly make a difference for patients. What we...
The Truth About Pharmaceuticals w/ Ravi Mehrotra 29.06.2021 25:08
As it turns out, many perceptions about the pharmaceutical industry are based without all of the facts. That’s why we’re sitting down to understand the data with Ravi Mehrotra, Thought Leader and former Senior Managing Director of Biotechnology Equity Research at Evercore ISI. What we talked about: - Defining WBPI while taking a closer look at the industry - The reality that winners pay for all th...
Similar podcasts
Replaio is not a podcast publisher; show names, artwork and audio belong to their authors and are distributed through public RSS feeds.